Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 0.94 |
| ▸ | KDR | P35968 | 10/20 | 0.94 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.64 |
| ▸ | SRC | P12931 | 4/20 | 0.62 |
| ▸ | ABL1 | P00519 | 3/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.62 |
| ▸ | PRKDC | P78527 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | HCK | P08631 | 2/20 | 0.61 |
| ▸ | MTOR | P42345 | 2/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455810 | 0.97 | RET (1.00) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL19463767 | 0.97 | RET (1.00) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL19492187 | 0.92 | RET (0.83) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL16655548 | 0.88 | RET (0.78) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL19463360 | 0.88 | RET (1.00) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL12422337 | 0.87 | PIK3CD (0.84) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL30455644 | 0.86 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CG | |
| SCHEMBL19492253 | 0.86 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CG | |
| SCHEMBL19492252 | 0.86 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CG | |
| SCHEMBL16655669 | 0.86 | RET (0.74) | RETKDRPIK3CDSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2385053-B1 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | disclosed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | disclosed |
| US-7651687-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | RET 744/4885KDR 2434/4885PIK3CD 57/4885 |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | RET 16/4885KDR 112/4885PIK3CD 71/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | RET 1023/4885KDR 979/4885PIK3CD 17/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | RET 60/4885KDR 532/4885PIK3CD 272/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | RET 1262/4885KDR 1245/4885PIK3CD 121/4885 |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | MTOR, RICTOR, MAPKAP1 | RET 744/4885KDR 2434/4885PIK3CD 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.